Medexus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Medexus Pharmaceuticals has a total shareholder equity of $29.6M and total debt of $51.7M, which brings its debt-to-equity ratio to 174.9%. Its total assets and total liabilities are $160.4M and $130.8M respectively. Medexus Pharmaceuticals's EBIT is $12.8M making its interest coverage ratio 0.9. It has cash and short-term investments of $8.2M.
Key information
174.9%
Debt to equity ratio
US$51.70m
Debt
Interest coverage ratio | 0.9x |
Cash | US$8.21m |
Equity | US$29.56m |
Total liabilities | US$130.82m |
Total assets | US$160.38m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: P731's short term assets ($74.1M) exceed its short term liabilities ($66.5M).
Long Term Liabilities: P731's short term assets ($74.1M) exceed its long term liabilities ($64.3M).
Debt to Equity History and Analysis
Debt Level: P731's net debt to equity ratio (147.1%) is considered high.
Reducing Debt: P731's debt to equity ratio has increased from 39% to 174.9% over the past 5 years.
Debt Coverage: P731's debt is well covered by operating cash flow (40.6%).
Interest Coverage: P731's interest payments on its debt are not well covered by EBIT (0.9x coverage).